[{"id":"b6c77732-afc6-4da0-815e-7108b1d9bd90","acronym":"","url":"https://clinicaltrials.gov/study/NCT00450944","created_at":"2021-01-18T01:35:50.105Z","updated_at":"2024-07-02T16:36:31.946Z","phase":"Phase 1","brief_title":"Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00450944","lead_sponsor":"Albert Einstein College of Medicine","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Combotox (Imtox19/Imtox22)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 02/22/2006","start_date":" 02/22/2006","primary_txt":" Primary completion: 10/27/2008","primary_completion_date":" 10/27/2008","study_txt":" Completion: 04/01/2010","study_completion_date":" 04/01/2010","last_update_posted":"2021-04-14"}]